echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Jiahe Biotech EGFR/c-Met/c-Met trispecific antibody applied for clinical application

    Jiahe Biotech EGFR/c-Met/c-Met trispecific antibody applied for clinical application

    • Last Update: 2022-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    On March 29, CDE's official website showed that Jiahe Bio's application for clinical trials of EGFR/c-Met/c-Met trispecific antibodies in China was accepted by the State Food and Drug Administration


    GB263T is the world's first EGFR/c-Met/c-Met trispecific antibody, targeting EGFR and two different c-Met epitopes


    In vitro studies and in vivo animal models have demonstrated its antitumor activity


    The antitumor activity of GB263T was evaluated in multiple tumor models including Ba/F3 EGFR-D770del-insGY, Ba/F3 EGFR-D770-N771-insSVD, Ba/F3

    EGFR-ex19del/T790M/C797S, HCC827/ER1, LU2503 PDX model (c-Met exon 14 skipping mutation), etc.


    In the cynomolgus monkey toxicology study, even in the high-dose group, no significant adverse reactions were observed after 4 weeks of administration


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.